| # | Title | Journal | Year | Citations |
|---|
| 1 | The size and burden of mental disorders and other disorders of the brain in Europe 2010 | European Neuropsychopharmacology | 2011 | 2,930 |
| 2 | Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015 | JAMA - Journal of the American Medical Association | 2017 | 1,492 |
| 3 | Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study | Lancet, The | 2016 | 1,414 |
| 4 | Defeating Alzheimer's disease and other dementias: a priority for European science and society | Lancet Neurology, The | 2016 | 1,242 |
| 5 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia | JAMA - Journal of the American Medical Association | 2015 | 1,166 |
| 6 | The economic cost of brain disorders in Europe | European Journal of Neurology | 2012 | 1,163 |
| 7 | Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine | New England Journal of Medicine | 2004 | 1,118 |
| 8 | Cgrp May Play A Causative Role in Migraine | Cephalalgia | 2002 | 852 |
| 9 | New Appendix Criteria Open for a Broader Concept of Chronic Migraine | Cephalalgia | 2006 | 846 |
| 10 | Vestibular migraine: Diagnostic criteria | Journal of Vestibular Research: Equilibrium and Orientation | 2012 | 787 |
| 11 | Cost of disorders of the brain in Europe | European Journal of Neurology | 2005 | 714 |
| 12 | European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage | International Journal of Stroke | 2014 | 638 |
| 13 | Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial | Lancet Neurology, The | 2017 | 589 |
| 14 | Timing and topography of cerebral blood flow, aura, and headache during migraine attacks | Annals of Neurology | 1990 | 538 |
| 15 | Migraine With Aura and Migraine Without Aura: An Epidemiological Study | Cephalalgia | 1992 | 535 |
| 16 | Epidemiology and comorbidity of headache | Lancet Neurology, The | 2008 | 523 |
| 17 | Prevalence of Amyloid PET Positivity in Dementia Syndromes | JAMA - Journal of the American Medical Association | 2015 | 501 |
| 18 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial | Lancet, The | 2011 | 485 |
| 19 | Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study | Lancet Neurology, The | 2017 | 472 |
| 20 | Central Sensitization in Tension-Type Headache—Possible Pathophysiological Mechanisms | Cephalalgia | 2000 | 469 |
| 21 | Origin of pain in migraine: evidence for peripheral sensitisation | Lancet Neurology, The | 2009 | 458 |
| 22 | Triptans in Migraine | Drugs | 2000 | 442 |
| 23 | A nosographic analysis of the migraine aura in a general population | Brain | 1996 | 425 |
| 24 | Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle | Pain | 1993 | 413 |
| 25 | Migraine is first cause of disability in under 50s: will health politicians now take notice? | Journal of Headache and Pain | 2018 | 408 |
| 26 | Prevalence and Sex-Ratio of the Subtypes of Migraine | International Journal of Epidemiology | 1995 | 400 |
| 27 | Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors | Magnetic Resonance in Medicine | 1990 | 399 |
| 28 | Migraine | New England Journal of Medicine | 2020 | 376 |
| 29 | PACAP38 induces migraine-like attacks in patients with migraine without aura | Brain | 2009 | 360 |
| 30 | Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019 | Journal of Headache and Pain | 2020 | 359 |
| 31 | Risk of COVID-19 in health-care workers in Denmark: an observational cohort study | Lancet Infectious Diseases, The | 2020 | 357 |
| 32 | Trigeminal neuralgia – diagnosis and treatment | Cephalalgia | 2017 | 342 |
| 33 | Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics | Pain | 1989 | 340 |
| 34 | Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial | Lancet Neurology, The | 2014 | 333 |
| 35 | EFNS guideline on the treatment of tension‐type headache – Report of an EFNS task force | European Journal of Neurology | 2010 | 328 |
| 36 | Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators | Cephalalgia | 2012 | 326 |
| 37 | European Academy of Neurology guideline on trigeminal neuralgia | European Journal of Neurology | 2019 | 324 |
| 38 | Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions | Lancet Neurology, The | 2016 | 321 |
| 39 | Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial | Lancet Neurology, The | 2016 | 312 |
| 40 | Increased familial risk and evidence of genetic factor in migraine | BMJ: British Medical Journal | 1995 | 312 |
| 41 | Migraine: epidemiology and systems of care | Lancet, The | 2021 | 310 |
| 42 | Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study | Cephalalgia | 2013 | 308 |
| 43 | Migraine Without Aura and Migraine with Aura Are Distinct Clinical Entities: A Study of Four Hundred and Eighty-Four Male and Female Migraineurs From the General Population | Cephalalgia | 1996 | 303 |
| 44 | Idiopathic intracranial hypertension: consensus guidelines on management | Journal of Neurology, Neurosurgery and Psychiatry | 2018 | 303 |
| 45 | Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis | Brain Pathology | 2007 | 301 |
| 46 | Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain | NeuroReport | 1993 | 296 |
| 47 | Migraine and the trigeminovascular system—40 years and counting | Lancet Neurology, The | 2019 | 294 |
| 48 | Temporomandibular disorders: Old ideas and new concepts | Cephalalgia | 2017 | 287 |
| 49 | A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks | European Journal of Neurology | 1994 | 281 |
| 50 | Migraine can be induced by sildenafil without changes in middle cerebral artery diameter | Brain | 2003 | 272 |
